Join
Live feed
·
INSIDERFilingvia Quantisnow
Arbutus Biopharma Corporation logo

Interim President & CEO Mcelhaugh Michael J. was granted 177,000 shares, increasing direct ownership by 12% to 1,658,003 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
ABUS· Arbutus Biopharma Corporation
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ABUS (Arbutus Biopharma Corporation) and more on Quantisnow.